We are live on ! Find out more
LOGC

LogicBio Therapeutics, Inc. Common Stock
LOGC

Delisted

LOGC was delisted on the 15th of November, 2022.

Back to rankings

Fund managers haven’t disclosed any holdings of LOGC yet.

LOGC Hedge Fund Activity: Q4 2022 in Review

0 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q4 2022, worth a combined $0 — down 100% from $513K a quarter earlier.

Sellers outnumbered buyers: 39 funds closed out of LOGC and 0 opened new positions — a net loss of 39 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $136K sold.

  • 0 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q4 2022, down from 39 in Q3 2022.
  • Funds reported $0 of LogicBio Therapeutics, Inc. Common Stock stock for Q4 2022, down 100% quarter-over-quarter.
  • 0 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q4 2022 and 39 closed out, a net change of -39 holders.
  • The largest LogicBio Therapeutics, Inc. Common Stock seller in Q4 2022 was Vanguard Group, an estimated $136K sold.

Based on aggregated 13F filings for Q4 2022.